Increased Incidence in Hospitalised Patients with Sudden Sensorineural Hearing Loss: a 14-year Nationwide Population-based Study
Overview
Affiliations
To conduct a 14-year nationwide study on the epidemiologic incidence in patients with sudden sensorineural hearing loss (SSNHL). Retrospective cross-sectional design. Data of patients hospitalised with the diagnosis of SSNHL from 2000 to 2013, extracted from the Taiwan National Health Insurance Research Database. In total, 31,258 patients were included. The mean age was 50.30 ± 16.70 years. Males (53.5%) were more commonly diagnosed with SSNHL than females (46.5%). The patients most commonly presented with SSNHL were in the age group of 45-64 years. The crude incidence of SSNHL from 2000 to 2013 was 9.76 per 100,000 people per year. The annual incidence rate shows a steady increased from 5.15 in 2000 to 13.97 per 100,000 people in 2013 with a statistical significance ( < 0.001). This 14-year nationwide study indicated an increased incidence rate of SSNHL. This necessitates the development of additional treatment modalities to enhance the prognosis and the clarification of the underlying mechanism of this enigmatic disease.
Li B, Xu X, Wu Y, Miao X, Feng Y, Chen Y Brain Commun. 2024; 6(5):fcae317.
PMID: 39318785 PMC: 11420982. DOI: 10.1093/braincomms/fcae317.
Increased risk of sudden sensorineural hearing loss in patients with cervical spondylosis.
Liu C, Chen I, Weng S Sci Rep. 2024; 14(1):2910.
PMID: 38316838 PMC: 10844319. DOI: 10.1038/s41598-024-52875-x.
Altered static and dynamic intrinsic brain activity in unilateral sudden sensorineural hearing loss.
Li J, Yu X, Zou Y, Leng Y, Yang F, Liu B Front Neurosci. 2023; 17:1257729.
PMID: 37719156 PMC: 10500124. DOI: 10.3389/fnins.2023.1257729.
Sudden Hearing Loss Following Vaccination Against COVID-19.
Nieminen T, Kivekas I, Artama M, Nohynek H, Kujansivu J, Hovi P JAMA Otolaryngol Head Neck Surg. 2022; 149(2):133-140.
PMID: 36520464 PMC: 9857204. DOI: 10.1001/jamaoto.2022.4154.
Zhang Y, Jia X, Liu X, Zhao L, Zhou Y, Liang F Evid Based Complement Alternat Med. 2022; 2022:1368783.
PMID: 36330225 PMC: 9626202. DOI: 10.1155/2022/1368783.